Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon May 28, 2022 2:36pm
134 Views
Post# 34714658

RE:RE:Andrew Schutte increases position in Replicel

RE:RE:Andrew Schutte increases position in ReplicelWho knows !   The total shares controlled by Mainpointe may not include warrants as well which would make the percental controlled by the Schutte family even higher.

The point here for me is this family has taken a very keen interest in Replicel's future.   Being partners on one hand and Andrew Schutte being a Director they obviously are privy to information that the rest of us don't have.  I guess that indirectly is good for us who are presently being kept in the dark.  They maybe holding back information until the private placement closes on June 6th. Regardless I am becoming increasingly p-ssed off with this lack of transparancy.
On the other hand something is definetley brewing here.  One of many options is that the company will be taken private and the shareholders will be bought out.  
<< Previous
Bullboard Posts
Next >>